231 related articles for article (PubMed ID: 22926602)
1. Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia.
Schuster JP; Raucher-Chéné D; Lemogne C; Rouillon F; Gasquet I; Leguay D; Gierski F; Azorin JM; Limosin F
J Clin Psychopharmacol; 2012 Oct; 32(5):672-7. PubMed ID: 22926602
[TBL] [Abstract][Full Text] [Related]
2. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
Lee SY; Park MH; Patkar AA; Pae CU
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):490-6. PubMed ID: 21146575
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Stroup TS; McEvoy JP; Ring KD; Hamer RH; LaVange LM; Swartz MS; Rosenheck RA; Perkins DO; Nussbaum AM; Lieberman JA;
Am J Psychiatry; 2011 Sep; 168(9):947-56. PubMed ID: 21768610
[TBL] [Abstract][Full Text] [Related]
4. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
[TBL] [Abstract][Full Text] [Related]
5. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
6. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
van Winkel R; De Hert M; Wampers M; Van Eyck D; Hanssens L; Scheen A; Peuskens J
J Clin Psychiatry; 2008 Mar; 69(3):472-9. PubMed ID: 18348593
[TBL] [Abstract][Full Text] [Related]
7. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
[TBL] [Abstract][Full Text] [Related]
8. Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs.
Moons T; Claes S; Martens GJ; Peuskens J; Van Loo KM; Van Schijndel JE; De Hert M; van Winkel R
Schizophr Res; 2011 Feb; 125(2-3):187-93. PubMed ID: 21050724
[TBL] [Abstract][Full Text] [Related]
9. [Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study].
Carpiniello B; Mellino G; Pintore S; Puddu L; Pinna F
Clin Ter; 2011; 162(4):331-41. PubMed ID: 21912821
[TBL] [Abstract][Full Text] [Related]
10. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
11. [Expectations and developments in atypical antipsychotics].
Praxis (Bern 1994); 2004 Aug; 93(35):1392. PubMed ID: 15468579
[No Abstract] [Full Text] [Related]
12. Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia.
Karagianis J; Williams R; Davis L; Procyshyn R; Monga N; Hanley J; Chandrasena R; Thakur A; Dickson R
Curr Med Res Opin; 2009 Sep; 25(9):2121-32. PubMed ID: 19601707
[TBL] [Abstract][Full Text] [Related]
13. TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment.
Huang HH; Wang YC; Wu CL; Hong CJ; Bai YM; Tsai SJ; Liou YJ
Neurosci Lett; 2011 Oct; 504(3):277-80. PubMed ID: 21967963
[TBL] [Abstract][Full Text] [Related]
14. Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.
Kolotkin RL; Corey-Lisle PK; Crosby RD; Kan HJ; McQuade RD
Eur Psychiatry; 2008 Dec; 23(8):561-6. PubMed ID: 18374544
[TBL] [Abstract][Full Text] [Related]
15. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
16. Cochrane for clinicians. Aripiprazole vs. other atypical antipsychotics for schizophrenia.
Guirguis-Blake J
Am Fam Physician; 2010 Jun; 81(11):1335-6. PubMed ID: 20521753
[No Abstract] [Full Text] [Related]
17. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
Simpson MM; Goetz RR; Devlin MJ; Goetz SA; Walsh BT
J Clin Psychiatry; 2001 Sep; 62(9):694-700. PubMed ID: 11681765
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course.
Gebhardt S; Haberhausen M; Heinzel-Gutenbrunner M; Gebhardt N; Remschmidt H; Krieg JC; Hebebrand J; Theisen FM
J Psychiatr Res; 2009 Mar; 43(6):620-6. PubMed ID: 19110264
[TBL] [Abstract][Full Text] [Related]
19. A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole.
Schorr SG; Slooff CJ; Postema R; Van Oven W; Schilthuis M; Bruggeman R; Taxis K
Acta Psychiatr Scand; 2008 Sep; 118(3):246-50. PubMed ID: 18699955
[TBL] [Abstract][Full Text] [Related]
20. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]